CPOs and
C. auris Prevention
Multidrug-resistant organisms (MDROs) are a growing problem globally and an emerging threat in Oregon. Carbapenemase-producing organisms (CPO) are an epidemiologically important group of multidrug-resistant pathogens classified by the Centers for Disease Control and Prevention (CDC) as an urgent threat to public health. Infections caused by CPO are difficult to treat and are associated with high mortality.
Another focus is
Candida auris (C. auris), a fungus that can colonize the skin, cause invasive infections, and has demonstrated resistance to common antifungal drugs. Some strains are resistant to all available classes of antifungals. It can spread readily among patients in healthcare facilities and persists for long periods of time in the environment or on contaminated medical equipment, causing numerous outbreaks that have been difficult to control.
Early detection and implementation of infection prevention and control strategies are imperative to prevent further spread of CPOs and
C. auris. Read more about our comprehensive approach below.
Surveillance and Response
We collaborate closely with healthcare facilities in Oregon to conduct regular point prevalence surveys,
infection control assessments, and laboratory surveillance. If a patient with a CPO or
C. auris is detected, we support healthcare facilities to rapidly implement containment and response measures.
We partner with facilities to screen patients upon admission. When patients meet risk criteria, testing helps us identify CPOs and Candida auris early. Early detection means quicker action and safety for all patients.
DROP-CRE Network
The Drug-Resistant Organism Prevention and Coordinated Regional Epidemiology (DROP-CRE) Network is a long-standing partnership among public health, healthcare, and academic institutions. The network develops toolkits, leads education efforts, and provides expert support for the prevention and control of MDROs in Oregon.
We provide guidance, tools, and technical support so local public health authorities (LPHAs) can respond to MDROs in their communities. Our goal is to safeguard public health by mitigating the spread of these resistant germs. Through our collaborative efforts, we can reduce their impact on patient well-being and health care safety.
Resources
C auris
Provider FAQ
Screening Patient FAQ
Wallet Card
CPO
Provider FAQ
Screening Patient FAQ
Infected Colonized Patient FAQ
Wallet Card